You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK)IMM2510獲批進行二期臨床試驗
阿思達克 11-07 16:38
宜明昂科-B(01541.HK)公布,集團自主研發靶向血管內皮生長因子(VEGF)及程序性細胞死亡配體1 (PD-L1)的雙特異性分子產品「IMM2510」,近日獲得國家藥監局批准,進行聯合化療一線治療非小細胞肺癌(NSCLC)或三陰性乳腺癌(TNBC)的二期臨床試驗。 公司表示,IMM2510一期臨床試驗的初步數據顯示出良好的安全性及積極的療效,一期劑量遞增研究的初步數據則顯示,其對於治療復發難治的肺腺癌、肺鱗癌及胸腺癌具有積極的療效。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account